BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21-26. [PMID: 17097388 DOI: 10.1016/j.jaad.2006.10.047] [Cited by in Crossref: 361] [Cited by in F6Publishing: 282] [Article Influence: 24.1] [Reference Citation Analysis]
Number Citing Articles
1 Penfield JG, Reilly RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3:654-668. [PMID: 18033225 DOI: 10.1038/ncpneph0660] [Cited by in Crossref: 241] [Cited by in F6Publishing: 191] [Article Influence: 18.5] [Reference Citation Analysis]
2 Le Fur M, Caravan P. The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics 2019;11:240-54. [PMID: 30516229 DOI: 10.1039/c8mt00302e] [Cited by in Crossref: 55] [Cited by in F6Publishing: 13] [Article Influence: 55.0] [Reference Citation Analysis]
3 Zhu L, Zhu L, Shi H, Wang H, Yan J, Liu B, Chen W, He J, Zhou Z, Yang X, Liu T. Evaluating early response of cervical cancer under concurrent chemo-radiotherapy by intravoxel incoherent motion MR imaging. BMC Cancer 2016;16:79. [PMID: 26860361 DOI: 10.1186/s12885-016-2116-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
4 Kuo PH. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications. AJR Am J Roentgenol 2008;191:1861-3. [PMID: 19020260 DOI: 10.2214/AJR.08.1179] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
5 Zhu L, Zhu L, Wang H, Yan J, Liu B, Chen W, He J, Zhou Z, Yang X. Predicting and Early Monitoring Treatment Efficiency of Cervical Cancer Under Concurrent Chemoradiotherapy by Intravoxel Incoherent Motion Magnetic Resonance Imaging: . Journal of Computer Assisted Tomography 2017;41:422-9. [DOI: 10.1097/rct.0000000000000550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Wang W, Lazar A. Diseases of collagen and elastic tissue. McKee's Pathology of the Skin. Elsevier; 2012. pp. 935-66. [DOI: 10.1016/b978-1-4160-5649-2.00021-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Perrotta G, Metens T, Absil J, Lemort M, Manto M. Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study. J Neurol 2017;264:2277-83. [PMID: 28956156 DOI: 10.1007/s00415-017-8631-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
8 Cowper SE. Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium. Advances in Dermatology 2007;23:131-54. [DOI: 10.1016/j.yadr.2007.07.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
9 Parsons AC, Yosipovitch G, Sheehan DJ, Sangüeza OP, Greenberg CS, Sane DC. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 2007;29:433-6. [PMID: 17890909 DOI: 10.1097/DAD.0b013e318156e43f] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
11 Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157. [PMID: 17267695 DOI: 10.1148/radiol.2431062144] [Cited by in Crossref: 715] [Cited by in F6Publishing: 544] [Article Influence: 51.1] [Reference Citation Analysis]
12 Kong Y, Zhang S, Wang J, Han C, Yu N, Liu Q, Wang W, Xu K. Potential toxicity evaluation and comparison within multiple mice organs after repeat injections of linear versus macrocyclic gadolinium-based contrast agents: A comprehensive and time course study. Toxicol Lett 2021;350:152-61. [PMID: 34311048 DOI: 10.1016/j.toxlet.2021.07.016] [Reference Citation Analysis]
13 Turgutalp K, Kiykim A, Özhan O, Helvaci I, Ozcan T, Yildiz A. Comparison of diagnostic accuracy of Doppler USG and contrast-enhanced magnetic resonance angiography and selective renal arteriography in patients with atherosclerotic renal artery stenosis. Med Sci Monit 2013;19:475-82. [PMID: 23778330 DOI: 10.12659/MSM.889035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
14 Saab G, Cheng S. Nephrogenic systemic fibrosis: a nephrologist's perspective. Hemodial Int 2007;11 Suppl 3:S2-6. [PMID: 17897106 DOI: 10.1111/j.1542-4758.2007.00222.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
15 Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. European Journal of Radiology 2008;66:230-4. [DOI: 10.1016/j.ejrad.2008.02.011] [Cited by in Crossref: 223] [Cited by in F6Publishing: 160] [Article Influence: 17.2] [Reference Citation Analysis]
16 Czeyda-Pommersheim F, Martin DR, Costello JR, Kalb B. Contrast Agents for MR Imaging. Magn Reson Imaging Clin N Am 2017;25:705-11. [PMID: 28964460 DOI: 10.1016/j.mric.2017.06.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Feng M, Fan YZ, Ma XJ, Li JX, Yang XG. The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation. Metallomics 2015;7:1103-10. [PMID: 25867453 DOI: 10.1039/c5mt00055f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol 2013;35:351-6. [PMID: 23051628 DOI: 10.1097/DAD.0b013e31826c5508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'malley RB, Parsons DJ, Fuller ER, Semelka RC. Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities. Radiology 2008;248:799-806. [DOI: 10.1148/radiol.2483072093] [Cited by in Crossref: 138] [Cited by in F6Publishing: 112] [Article Influence: 10.6] [Reference Citation Analysis]
20 Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol. 2009;16:897-905. [PMID: 19375360 DOI: 10.1016/j.acra.2009.01.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
21 High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:710-2. [PMID: 17289213 DOI: 10.1016/j.jaad.2007.01.022] [Cited by in Crossref: 122] [Cited by in F6Publishing: 97] [Article Influence: 8.7] [Reference Citation Analysis]
22 Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, Singh S, Fuchsjäger M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 2012;81:2562-7. [PMID: 22304979 DOI: 10.1016/j.ejrad.2011.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015;41:1259-67. [PMID: 24811860 DOI: 10.1002/jmri.24650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
24 Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190:1060-8. [PMID: 18356456 DOI: 10.2214/AJR.07.2822] [Cited by in Crossref: 112] [Cited by in F6Publishing: 24] [Article Influence: 8.6] [Reference Citation Analysis]
25 Kanal E, Patton TJ, Krefting I, Wang C. Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration. AJNR Am J Neuroradiol 2020;41:393-9. [PMID: 32115422 DOI: 10.3174/ajnr.A6448] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Perazella MA, Rodby RA. Gadolinium-Induced Nephrogenic Systemic Fibrosis in Patients with Kidney Disease. The American Journal of Medicine 2007;120:561-2. [DOI: 10.1016/j.amjmed.2007.01.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
27 Colletti PM. Nephrogenic systemic fibrosis and gadolinium: a perfect storm. AJR Am J Roentgenol 2008;191:1150-3. [PMID: 18806157 DOI: 10.2214/AJR.08.1327] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Liu H, Zhang J, Chen X, Du XS, Zhang JL, Liu G, Zhang WG. Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside. Nanoscale 2016;8:7808-26. [PMID: 27029509 DOI: 10.1039/c6nr00147e] [Cited by in Crossref: 65] [Cited by in F6Publishing: 19] [Article Influence: 16.3] [Reference Citation Analysis]
29 Hazelton JM, Chiu MK, Abujudeh HH. Nephrogenic Systemic Fibrosis: A Review of History, Pathophysiology, and Current Guidelines. Curr Radiol Rep 2019;7. [DOI: 10.1007/s40134-019-0312-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Gibbons RJ, Araoz PA, Williamson EE. The Year in Cardiac Imaging. Journal of the American College of Cardiology 2007;50:988-1003. [DOI: 10.1016/j.jacc.2007.05.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
31 Rowe MD, Thamm DH, Kraft SL, Boyes SG. Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. Biomacromolecules 2009;10:983-93. [PMID: 19290624 DOI: 10.1021/bm900043e] [Cited by in Crossref: 212] [Cited by in F6Publishing: 160] [Article Influence: 19.3] [Reference Citation Analysis]
32 Murphy DJ, Kwong RY. Contrast Agents in Cardiovascular Magnetic Resonance Imaging. In: Kwong RY, Jerosch-herold M, Heydari B, editors. Cardiovascular Magnetic Resonance Imaging. New York: Springer; 2019. pp. 127-43. [DOI: 10.1007/978-1-4939-8841-9_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
34 Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88. [PMID: 18440117 DOI: 10.1016/j.tox.2008.03.012] [Cited by in Crossref: 114] [Cited by in F6Publishing: 87] [Article Influence: 8.8] [Reference Citation Analysis]
35 Wáng YX, Schroeder J, Siegmund H, Idée JM, Fretellier N, Jestin-Mayer G, Factor C, Deng M, Kang W, Morcos SK. Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats. Quant Imaging Med Surg 2015;5:534-45. [PMID: 26435917 DOI: 10.3978/j.issn.2223-4292.2015.05.03] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
36 Rahatli FK, Donmez FY, Kibaroglu S, Kesim C, Haberal KM, Turnaoglu H, Agildere AM. Does renal function affect gadolinium deposition in the brain? Eur J Radiol 2018;104:33-7. [PMID: 29857863 DOI: 10.1016/j.ejrad.2018.04.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
37 Samtleben W. [Nephrogenic systemic fibrosis]. Radiologe 2007;47:778-84. [PMID: 17717643 DOI: 10.1007/s00117-007-1545-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
38 Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients. Radiology 2009;253:81-9. [DOI: 10.1148/radiol.2531082160] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
39 Hoda RS, Sanyal S, Abraham JL, Everett JM, Hundemer GL, Yee E, Lauwers GY, Tolkoff-Rubin N, Misdraji J. Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract. Histopathology. 2017;70:1072-1078. [PMID: 28134986 DOI: 10.1111/his.13178] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
40 Campbell JL, Arora J, Cowell SF, Garg A, Eu P, Bhargava SK, Bansal V. Quasi-cubic magnetite/silica core-shell nanoparticles as enhanced MRI contrast agents for cancer imaging. PLoS One 2011;6:e21857. [PMID: 21747962 DOI: 10.1371/journal.pone.0021857] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
41 Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007;72:260-4. [PMID: 17507905 DOI: 10.1038/sj.ki.5002338] [Cited by in Crossref: 192] [Cited by in F6Publishing: 145] [Article Influence: 13.7] [Reference Citation Analysis]
42 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
43 Erdene K, Nakajima T, Kameo S, Khairinisa MA, Lamid-ochir O, Tumenjargal A, Koibuchi N, Koyama H, Tsushima Y. Organ retention of gadolinium in mother and pup mice: effect of pregnancy and type of gadolinium-based contrast agents. Jpn J Radiol 2017;35:568-73. [DOI: 10.1007/s11604-017-0667-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
44 McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015;275:772-782. [PMID: 25742194 DOI: 10.1148/radiol.15150025] [Cited by in Crossref: 827] [Cited by in F6Publishing: 665] [Article Influence: 137.8] [Reference Citation Analysis]
45 Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG, Froelich JW, Gilk T, Gimbel JR, Gosbee J, Kuhni-kaminski E, Lester JW, Nyenhuis J, Parag Y, Schaefer DJ, Sebek-scoumis EA, Weinreb J, Zaremba LA, Wilcox P, Lucey L, Sass N. ACR Guidance Document for Safe MR Practices: 2007. American Journal of Roentgenology 2007;188:1447-74. [DOI: 10.2214/ajr.06.1616] [Cited by in Crossref: 523] [Cited by in F6Publishing: 107] [Article Influence: 37.4] [Reference Citation Analysis]
46 Prasad SR, Jagirdar J. Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy: A Primer for Radiologists. Journal of Computer Assisted Tomography 2008;32:1-3. [DOI: 10.1097/rct.0b013e31805d08ee] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
47 Matson ML, Wilson LJ. Nanotechnology and MRI contrast enhancement. Future Medicinal Chemistry 2010;2:491-502. [DOI: 10.4155/fmc.10.3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
48 Rota E, Nallino MG, Bainotti S, Formica M. Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder. Rheumatol Int 2010;30:1389-91. [PMID: 19693506 DOI: 10.1007/s00296-009-1083-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Pasquini L, Napolitano A, Visconti E, Longo D, Romano A, Tomà P, Rossi Espagnet MC. Gadolinium-Based Contrast Agent-Related Toxicities. CNS Drugs 2018;32:229-40. [PMID: 29508245 DOI: 10.1007/s40263-018-0500-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
50 Le Fur M, Rotile NJ, Correcher C, Clavijo Jordan V, Ross AW, Catana C, Caravan P. Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents. Angew Chem Int Ed Engl 2020;59:1474-8. [PMID: 31750991 DOI: 10.1002/anie.201911858] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
51 Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007;7:130-7. [PMID: 17905680 DOI: 10.1102/1470-7330.2007.0019] [Cited by in Crossref: 84] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
52 Nasir A. Nanotechnology and dermatology: Part II—risks of nanotechnology. Clinics in Dermatology 2010;28:581-8. [DOI: 10.1016/j.clindermatol.2009.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
53 Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. Appl Immunohistochem Mol Morphol 2010;18:448-52. [PMID: 20485155 DOI: 10.1097/PAI.0b013e3181de372e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
54 Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis Rheum 2007;56:3173-5. [DOI: 10.1002/art.22926] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
55 Perazella MA, Rodby RA. Editorial: Gadolinium Use in Patients with Kidney Disease: A Cause for Concern: GADOLINIUM USE IN PATIENTS WITH KIDNEY DISEASE. Seminars in Dialysis 2007;20:179-85. [DOI: 10.1111/j.1525-139x.2007.00269.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
56 Wang X, Huang J, Wang K, Neufurth M, Schröder HC, Wang S, Müller WE. The morphogenetically active polymer, inorganic polyphosphate complexed with GdCl 3 , as an inducer of hydroxyapatite formation in vitro. Biochemical Pharmacology 2016;102:97-106. [DOI: 10.1016/j.bcp.2015.12.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
57 Martin DR. Nephrogenic systemic fibrosis. Pediatr Radiol. 2008;38 Suppl 1:S125-S129. [PMID: 15168803 DOI: 10.1007/s00247-007-0589-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
58 Gallo CJR, Mammarappallil JG, Johnson DY, Chalian H, Ronald J, Bashir MR, Kim CY. Ferumoxytol-enhanced MR Venography of the Central Veins of the Thorax for the Evaluation of Stenosis and Occlusion in Patients with Renal Impairment. Radiol Cardiothorac Imaging 2020;2:e200339. [PMID: 33778639 DOI: 10.1148/ryct.2020200339] [Reference Citation Analysis]
59 Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425-2432. [PMID: 17711550 DOI: 10.1111/j.1600-6143.2007.01941.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
60 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
61 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
62 Lange S, Mędrzycka-Dąbrowska W, Zorena K, Dąbrowski S, Ślęzak D, Malecka-Dubiela A, Rutkowski P. Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review. Int J Environ Res Public Health 2021;18:3000. [PMID: 33804005 DOI: 10.3390/ijerph18063000] [Reference Citation Analysis]
63 Bahrainwala JZ, Leonberg-yoo AK, Rudnick MR. Use of Radiocontrast Agents in CKD and ESRD. Semin Dial 2017;30:290-304. [DOI: 10.1111/sdi.12593] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
64 Malhotra N, Hsu HS, Liang ST, Roldan MJM, Lee JS, Ger TR, Hsiao CD. An Updated Review of Toxicity Effect of the Rare Earth Elements (REEs) on Aquatic Organisms. Animals (Basel) 2020;10:E1663. [PMID: 32947815 DOI: 10.3390/ani10091663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
65 Cowper SE. Gadolinium – is it to blame? J Cutan Pathol 2008;35:520-2. [DOI: 10.1111/j.1600-0560.2008.01027.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
66 Liszewski MC, Görkem S, Sodhi KS, Lee EY. Lung magnetic resonance imaging for pneumonia in children. Pediatr Radiol 2017;47:1420-30. [PMID: 29043418 DOI: 10.1007/s00247-017-3865-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
67 Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007;18:2636-43. [PMID: 17855637 DOI: 10.1681/ASN.2007060645] [Cited by in Crossref: 103] [Cited by in F6Publishing: 25] [Article Influence: 7.4] [Reference Citation Analysis]
68 Morris MF, Zhang Y, Zhang H, Prowda JC, Silvers DN, Fawwaz RA, Prince MR. Features of nephrogenic systemic fibrosis on radiology examinations. AJR Am J Roentgenol 2009;193:61-9. [PMID: 19542396 DOI: 10.2214/AJR.08.1352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Jamboti J. Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Internal Medicine Journal 2007;37:508-9. [DOI: 10.1111/j.1445-5994.2007.01413.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
70 Thomsen HS, Morcos SK. Nephrogenic Systemic Fibrosis and Nonionic Linear Chelates. American Journal of Roentgenology 2007;188:W580-W580. [DOI: 10.2214/ajr.06.1651] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
71 Perazella MA, Reilly RF. Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 2011;341:215-21. [PMID: 21139495 DOI: 10.1097/MAJ.0b013e3181f016e6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
72 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
73 Mukundan S, Steigner ML, Hsiao LL, Malek SK, Tullius SG, Chin MS, Siedlecki AM. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD. Am J Kidney Dis 2016;67:984-8. [PMID: 26786296 DOI: 10.1053/j.ajkd.2015.12.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
74 Matsumoto Y, Mitsuhashi Y, Monma F, Kawaguchi M, Suzuki T, Miyabe C, Igarashi A, Tsuboi R. Nephrogenic systemic fibrosis: a case report and review on Japanese patients. J Dermatol 2012;39:449-53. [PMID: 22035371 DOI: 10.1111/j.1346-8138.2011.01407.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
75 Broome DR, Cottrell AC, Kanal E. Response to “Will Dialysis Prevent the Development of Nephrogenic Systemic Fibrosis After Gadolinium-Based Contrast Administration?”. American Journal of Roentgenology 2007;189:W234-5. [DOI: 10.2214/ajr.07.2919] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
76 Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-18. [PMID: 19404939 DOI: 10.1002/art.24471] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
77 Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63. [PMID: 18952698 DOI: 10.1093/ndt/gfn593] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
78 Miyamoto J, Tanikawa A, Igarashi A, Hataya H, Kobayashi K, Ikegami M, Sotome A, Nagai Y, Kameyama K, Ishiko A. Detection of iron deposition in dermal fibrocytes is a useful tool for histologic diagnosis of nephrogenic systemic fibrosis. Am J Dermatopathol 2011;33:271-6. [PMID: 21389836 DOI: 10.1097/DAD.0b013e3181f63eb1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
79 Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-93. [PMID: 18220317 DOI: 10.1002/path.2311] [Cited by in Crossref: 98] [Cited by in F6Publishing: 79] [Article Influence: 7.5] [Reference Citation Analysis]
80 Barbieri S, Schroeder C, Froehlich JM, Pasch A, Thoeny HC. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. Contrast Media Mol Imaging 2016;11:245-50. [PMID: 26929131 DOI: 10.1002/cmmi.1683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
81 Kubíček V, Tóth É. Design and function of metal complexes as contrast agents in MRI. Elsevier; 2009. pp. 63-129. [DOI: 10.1016/s0898-8838(09)00202-5] [Cited by in Crossref: 44] [Article Influence: 3.7] [Reference Citation Analysis]
82 Bumb A, Brechbiel MW, Choyke P. Macromolecular and dendrimer-based magnetic resonance contrast agents. Acta Radiol 2010;51:751-67. [PMID: 20590365 DOI: 10.3109/02841851.2010.491091] [Cited by in Crossref: 58] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
83 Perazella MA. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Semin Dial 2008;21:150-4. [PMID: 18226004 DOI: 10.1111/j.1525-139X.2007.00403.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
84 Li J, Liu J, Wang K, Yang X. Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells. J Biol Inorg Chem 2010;15:547-57. [DOI: 10.1007/s00775-010-0622-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
85 Miao Y, Xie F, Cen J, Zhou F, Tao X, Luo J, Han G, Kong X, Yang X, Sun J, Ling J. Fe 3+ @polyDOPA- b -polysarcosine, a T 1 -Weighted MRI Contrast Agent via Controlled NTA Polymerization. ACS Macro Lett 2018;7:693-8. [DOI: 10.1021/acsmacrolett.8b00287] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 8.7] [Reference Citation Analysis]
86 Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012;189:318-27. [PMID: 22649203 DOI: 10.4049/jimmunol.1103099] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
87 Deo A, Fogel M, Cowper SE. Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure. CJASN 2007;2:264-7. [DOI: 10.2215/cjn.03921106] [Cited by in Crossref: 200] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
88 Martin DR. Nephrogenic Systemic Fibrosis and Gadolinium-Enhanced Magnetic Resonance Imaging: Does a US Food and Drug Administration Alert Influence Practice Patterns in CKD? American Journal of Kidney Diseases 2010;56:427-30. [DOI: 10.1053/j.ajkd.2010.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
89 Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP, Serra AL. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009;75:235-41. [PMID: 18971924 DOI: 10.1038/ki.2008.558] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 7.2] [Reference Citation Analysis]
90 Marckmann P. Nephrogenic systemic fibrosis: epidemiology update: . Current Opinion in Nephrology and Hypertension 2008;17:315-9. [DOI: 10.1097/mnh.0b013e3282f4b605] [Cited by in Crossref: 32] [Article Influence: 2.5] [Reference Citation Analysis]
91 Webb JAW. Pregnancy and Lactation. In: Thomsen HS, Webb JAW, editors. Contrast Media. Berlin: Springer Berlin Heidelberg; 2009. pp. 95-101. [DOI: 10.1007/978-3-540-72784-2_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 2014;175:113-25. [PMID: 24111526 DOI: 10.1111/cei.12211] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
93 Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008;34:199-220; ix. [PMID: 18329541 DOI: 10.1016/j.rdc.2007.11.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
94 Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3:968-75. [PMID: 18385397 DOI: 10.2215/CJN.00100108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
95 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
96 Rowe MD, Chang CC, Thamm DH, Kraft SL, Harmon JF Jr, Vogt AP, Sumerlin BS, Boyes SG. Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. Langmuir 2009;25:9487-99. [PMID: 19422256 DOI: 10.1021/la900730b] [Cited by in Crossref: 100] [Cited by in F6Publishing: 76] [Article Influence: 8.3] [Reference Citation Analysis]
97 Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175. [PMID: 17704357 DOI: 10.1148/radiol.2451070353] [Cited by in Crossref: 247] [Cited by in F6Publishing: 187] [Article Influence: 17.6] [Reference Citation Analysis]
98 Hoppe H, Spagnuolo S, Froehlich JM, Nievergelt H, Dinkel H, Gretener S, Thoeny HC. Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents. Eur Radiol 2010;20:595-603. [DOI: 10.1007/s00330-009-1586-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
99 Lu C, Dong P, Pi L, Wang Z, Yuan H, Liang H, Ma D, Chai KY. Hydroxyl-PEG-Phosphonic Acid-Stabilized Superparamagnetic Manganese Oxide-Doped Iron Oxide Nanoparticles with Synergistic Effects for Dual-Mode MR Imaging. Langmuir 2019;35:9474-82. [PMID: 31241339 DOI: 10.1021/acs.langmuir.9b00736] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
100 Stafford RB, Sabati M, Mahallati H, Frayne R. 3D non-contrast-enhanced MR angiography with balanced steady-state free precession dixon method. Magn Reson Med 2008;59:430-3. [DOI: 10.1002/mrm.21479] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
101 Khurana A, Nickel AE, Greene JF, Narayanan M, High WA, Foulks CJ. Successful Pregnancy in a Hemodialysis Patient and Marked Resolution of Her Nephrogenic Systemic Fibrosis. American Journal of Kidney Diseases 2008;51:e29-32. [DOI: 10.1053/j.ajkd.2007.12.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
102 Knoepp F, Bettmer J, Fronius M. Gadolinium released by the linear gadolinium-based contrast-agent Gd-DTPA decreases the activity of human epithelial Na+ channels (ENaCs). Biochim Biophys Acta Biomembr 2017;1859:1040-8. [PMID: 28257815 DOI: 10.1016/j.bbamem.2017.02.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
103 Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. Ann Rheum Dis 2015;74:2062-9. [PMID: 24914072 DOI: 10.1136/annrheumdis-2013-204900] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
104 Gao S, George SJ, Zhou Z. Interaction of Gd-DTPA with phosphate and phosphite: toward the reaction intermediate in nephrogenic systemic fibrosis. Dalton Trans 2016;45:5388-94. [DOI: 10.1039/c5dt04172d] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
105 Wiginton CD. Implications of NSF-Active and NSF-Inert in Nephrogenic Systemic Fibrosis. American Journal of Roentgenology 2008;191:1864-6. [DOI: 10.2214/ajr.08.1410] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
106 Boyd AS, Sanyal S, Abraham JL. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? J Am Acad Dermatol 2010;62:337-42. [PMID: 19939504 DOI: 10.1016/j.jaad.2009.04.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
107 Kurtkoti J, Snow T, Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 2008;13:235-41. [PMID: 18221255 DOI: 10.1111/j.1440-1797.2007.00912.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
108 Perazella MA. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? Clin J Am Soc Nephrol 2008;3:649-51. [PMID: 18385396 DOI: 10.2215/CJN.00670208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
109 Chewning RH, Murphy KJ. Gadolinium-based Contrast Media and the Development of Nephrogenic Systemic Fibrosis in Patients with Renal Insufficiency. Journal of Vascular and Interventional Radiology 2007;18:331-3. [DOI: 10.1016/j.jvir.2007.01.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
110 Clases D, Fingerhut S, Jeibmann A, Sperling M, Doble P, Karst U. LA-ICP-MS/MS improves limits of detection in elemental bioimaging of gadolinium deposition originating from MRI contrast agents in skin and brain tissues. Journal of Trace Elements in Medicine and Biology 2019;51:212-8. [DOI: 10.1016/j.jtemb.2018.10.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
111 Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine 2008;3:201-13. [DOI: 10.2217/17435889.3.2.201] [Cited by in Crossref: 185] [Cited by in F6Publishing: 116] [Article Influence: 14.2] [Reference Citation Analysis]
112 Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009;47:855-69, vii. [PMID: 19744600 DOI: 10.1016/j.rcl.2009.06.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
113 Jiang W, Xie H, Ghoorah D, Shang Y, Shi H, Liu F, Yang X, Xu H. Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model. PLoS One 2012;7:e37376. [PMID: 22615995 DOI: 10.1371/journal.pone.0037376] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
114 Mohrs OK, Petersen SE, Heidt MC, Schulze T, Schmitt P, Bergemann S, Kauczor HU. High-resolution 3D non-contrast-enhanced, ECG-gated, multi-step MR angiography of the lower extremities: comparison with contrast-enhanced MR angiography. Eur Radiol 2011;21:434-42. [PMID: 20706840 DOI: 10.1007/s00330-010-1932-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
115 Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic Systemic Fibrosis and Its Impact on Abdominal Imaging. RadioGraphics 2009;29:1565-74. [DOI: 10.1148/rg.296095517] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
116 Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics. 2009;29:9-22. [PMID: 19019996 DOI: 10.1148/rg.291085072] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
117 Deng A, Martin DB, Spillane A, Chwalek J, St Surin-Lord S, Brooks S, Petrali J, Sina B, Gaspari A, Kao G. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 2010;37:204-10. [PMID: 19341434 DOI: 10.1111/j.1600-0560.2009.01301.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
118 Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017;53:306-36. [PMID: 28712039 DOI: 10.1007/s12016-017-8625-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 21.0] [Reference Citation Analysis]
119 Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. European Journal of Radiology 2008;66:200-7. [DOI: 10.1016/j.ejrad.2008.01.026] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
120 Cerwinka WH, Damien Grattan-Smith J, Kirsch AJ. Magnetic resonance urography in pediatric urology. J Pediatr Urol 2008;4:74-82; quiz 82-3. [PMID: 18631897 DOI: 10.1016/j.jpurol.2007.08.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
121 Martin DR, Semelka RC, Chapman A, Peters H, Finn PJ, Kalb B, Thomsen H. Nephrogenic systemic fibrosis versus contrast-induced nephropathy: Risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 2009;30:1350-6. [DOI: 10.1002/jmri.21968] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
122 Cowper SE. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol. 2008;5:23-28. [PMID: 18180005 DOI: 10.1016/j.jacr.2007.08.013] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
123 Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43. [PMID: 20663970 DOI: 10.1148/radiol.10091131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
124 Francès C, Senet P, Lipsker D. Fibrose systémique néphrogénique. La Revue de Médecine Interne 2011;32:358-62. [DOI: 10.1016/j.revmed.2009.07.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
125 Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008;21:135-9. [PMID: 18226001 DOI: 10.1111/j.1525-139X.2007.00406.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
126 Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;26:1190-7. [PMID: 17969161 DOI: 10.1002/jmri.21135] [Cited by in Crossref: 186] [Cited by in F6Publishing: 141] [Article Influence: 14.3] [Reference Citation Analysis]
127 Gou BD, Bian S, Zhang TL, Wang K. Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages. Toxicol In Vitro 2010;24:1743-9. [PMID: 20471468 DOI: 10.1016/j.tiv.2010.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
128 Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol 2008;190:1069-75. [PMID: 18356457 DOI: 10.2214/AJR.07.2884] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
129 Perazella MA, Reilly RF. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Recommendations for Gadolinium-Based Contrast Use in Patients with Kidney Disease: GUIDELINES OF GBC USE IN KIDNEY DISEASE. Seminars in Dialysis 2008;21:171-3. [DOI: 10.1111/j.1525-139x.2007.00402.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
130 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
131 Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol 2008;58:1025-30. [PMID: 18485985 DOI: 10.1016/j.jaad.2008.02.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
132 Martin DR. Nephrogenic system fibrosis: A radiologist's practical perspective. European Journal of Radiology 2008;66:220-4. [DOI: 10.1016/j.ejrad.2008.01.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
133 Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. Nephrogenic Systemic Fibrosis in Rats Treated with Erythropoietin and Intravenous Iron. Radiology 2009;253:390-8. [DOI: 10.1148/radiol.2532090580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
134 Weigle JP, Broome DR. Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 2008;37:457-64. [DOI: 10.1007/s00256-008-0464-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
135 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 23] [Article Influence: 6.9] [Reference Citation Analysis]
136 So K, Macquillan GC, Adams LA, Delriviere L, Mitchell A, Moody H, Wood DJ, Junckerstorff RC, Jeffrey GP. Malignant fibrous histiocytoma complicating nephrogenic systemic fibrosis post liver transplantation. Intern Med J. 2009;39:613-617. [PMID: 19769682 DOI: 10.1111/j.1445-5994.2009.01977.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
137 High WA. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Expert Review of Dermatology 2014;2:593-605. [DOI: 10.1586/17469872.2.5.593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
138 Shen L, Yang A, Yao P, Sun X, Chen C, Mo C, Shi L, Chen Y, Liu Q. Gadolinium promoted proliferation in mouse embryo fibroblast NIH3T3 cells through Rac and PI3K/Akt signaling pathways. Biometals 2014;27:753-62. [DOI: 10.1007/s10534-014-9769-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
139 Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aid. Journal of the American Academy of Dermatology 2011;64:741-7. [DOI: 10.1016/j.jaad.2010.05.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
140 Künnemeyer J, Terborg L, Nowak S, Telgmann L, Tokmak F, Krämer BK, Günsel A, Wiesmüller GA, Waldeck J, Bremer C, Karst U. Analysis of the Contrast Agent Magnevist and Its Transmetalation Products in Blood Plasma by Capillary Electrophoresis/Electrospray Ionization Time-of-Flight Mass Spectrometry. Anal Chem 2009;81:3600-7. [DOI: 10.1021/ac8027118] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
141 Yang HJ, Oksuz I, Dey D, Sykes J, Klein M, Butler J, Kovacs MS, Sobczyk O, Cokic I, Slomka PJ, Bi X, Li D, Tighiouart M, Tsaftaris SA, Prato FS, Fisher JA, Dharmakumar R. Accurate needle-free assessment of myocardial oxygenation for ischemic heart disease in canines using magnetic resonance imaging. Sci Transl Med 2019;11:eaat4407. [PMID: 31142677 DOI: 10.1126/scitranslmed.aat4407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
142 Hiwatashi A, Togao O, Yamashita K, Kikuchi K, Yoshikawa H, Obara M, Honda H. High Resolution Diffusion-Weighted Imaging for Solitary Orbital Tumors: 3D Turbo Field Echo with Diffusion-Sensitized Driven-Equilibrium (DSDE-TFE) Preparation Technique. Clin Neuroradiol 2018;28:261-6. [DOI: 10.1007/s00062-016-0556-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
143 Tear LR, Maguire ML, Tropiano M, Yao K, Farrer NJ, Faulkner S, Schneider JE. Enhancing 31P NMR relaxation rates with a kinetically inert gadolinium complex. Dalton Trans 2020;49:2989-93. [PMID: 32080690 DOI: 10.1039/c9dt03761f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
144 McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 2018;289:517-34. [PMID: 30204075 DOI: 10.1148/radiol.2018181151] [Cited by in Crossref: 121] [Cited by in F6Publishing: 79] [Article Influence: 40.3] [Reference Citation Analysis]
145 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
146 Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J. Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 2012;145:257-67. [PMID: 21882070 DOI: 10.1007/s12011-011-9176-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
147 Thakral C, Abraham JL. Nephrogenic Systemic Fibrosis: Histology and Gadolinium Detection. Radiologic Clinics of North America 2009;47:841-53. [DOI: 10.1016/j.rcl.2009.06.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
148 Singh M, Davenport A, Clatworthy I, Lewin J, Deroide F, Hubbard V, Rustin MH. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Br J Dermatol 2008;158:1358-62. [PMID: 18363754 DOI: 10.1111/j.1365-2133.2008.08506.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
149 Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;25:881-3. [DOI: 10.1002/jmri.20983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
150 Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009;4:461-469. [PMID: 19201920 DOI: 10.2215/cjn.06011108] [Cited by in Crossref: 178] [Cited by in F6Publishing: 64] [Article Influence: 14.8] [Reference Citation Analysis]
151 Gulati A, Harwood CA, Raftery M, Cerio R, Ashman N, Proby CA. Magnetic resonance imaging with gadolinium enhancement in renal failure: a need for caution. International Journal of Dermatology 2008;47:947-9. [DOI: 10.1111/j.1365-4632.2008.03655.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
152 Motegi S, Okada E, Uchiyama A, Yamada K, Ogino S, Yokoyama Y, Takeuchi Y, Monma F, Suzuki T, Ishikawa O. Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. Exp Dermatol 2014;23:664-9. [DOI: 10.1111/exd.12500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
153 Su HS, Nazarian RM, Scott JA. Appearance of nephrogenic fibrosing dermopathy on a bone scan. BJR 2009;82:e35-6. [DOI: 10.1259/bjr/20570152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
154 Kanda T, Oba H, Toyoda K, Kitajima K, Furui S. Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 2016;34:3-9. [DOI: 10.1007/s11604-015-0503-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 85] [Article Influence: 17.3] [Reference Citation Analysis]
155 George V, Tammisetti VS, Surabhi VR, Shanbhogue AK. Chronic Fibrosing Conditions in Abdominal Imaging. RadioGraphics 2013;33:1053-80. [DOI: 10.1148/rg.334125081] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
156 Kim CY, Mirza RA, Bryant JA, Whiting ED, Delong DM, Spritzer CE, Merkle EM. Central veins of the chest: evaluation with time-resolved MR angiography. Radiology 2008;247:558-66. [PMID: 18349313 DOI: 10.1148/radiol.2472070790] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
157 Goffin E, Schroeder JA, Weingart C, Decleire PY, Cosyns JP. Absence of gadolinium deposits in the peritoneal membrane of patients with encapsulating peritoneal sclerosis. Nephrology Dialysis Transplantation 2010;25:1334-9. [DOI: 10.1093/ndt/gfp664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
158 Prybylski JP, Maxwell E, Coste Sanchez C, Jay M. Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood-brain barrier. Magn Reson Imaging 2016;34:1366-72. [PMID: 27580521 DOI: 10.1016/j.mri.2016.08.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
159 Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, Brown HH, Shah SV. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008;73:1413-8. [PMID: 18401336 DOI: 10.1038/ki.2008.76] [Cited by in Crossref: 88] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
160 Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008;158:273-80. [PMID: 18067485 DOI: 10.1111/j.1365-2133.2007.08335.x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 126] [Article Influence: 10.9] [Reference Citation Analysis]
161 Zamora CA, Castillo M. Historical Perspective of Imaging Contrast Agents. Magn Reson Imaging Clin N Am 2017;25:685-96. [PMID: 28964458 DOI: 10.1016/j.mric.2017.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
162 Ozawa Y, Hayashi S, Hamasaki Y, Hatamochi A. Effects of Gadodiamide on cell proliferation and collagen production in cultured human dermal fibroblasts. Arch Dermatol Res 2016;308:695-701. [DOI: 10.1007/s00403-016-1689-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
163 Zhou Z, Wang L, Chi X, Bao J, Yang L, Zhao W, Chen Z, Wang X, Chen X, Gao J. Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging. ACS Nano 2013;7:3287-96. [PMID: 23473444 DOI: 10.1021/nn305991e] [Cited by in Crossref: 168] [Cited by in F6Publishing: 140] [Article Influence: 21.0] [Reference Citation Analysis]
164 Birka M, Wentker KS, Lusmöller E, Arheilger B, Wehe CA, Sperling M, Stadler R, Karst U. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem 2015;87:3321-8. [PMID: 25708271 DOI: 10.1021/ac504488k] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 15.8] [Reference Citation Analysis]
165 Kneepkens E, Fernandes A, Nicolay K, Grüll H. Iron(III)-Based Magnetic Resonance–Imageable Liposomal T1 Contrast Agent for Monitoring Temperature-Induced Image-Guided Drug Delivery. Invest Radiol 2016;51:735-45. [DOI: 10.1097/rli.0000000000000297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
166 Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J 2011;2:51-6. [PMID: 23130224 DOI: 10.4103/2229-5178.85990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
167 Neto JA, Elazzazzi M, Altun E, Semelka RC. When should abdominal magnetic resonance imaging be used? Clin Gastroenterol Hepatol 2008;6:610-5. [PMID: 18550003 DOI: 10.1016/j.cgh.2008.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
168 Meran S, Steadman R. Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol 2011;92:158-67. [PMID: 21355940 DOI: 10.1111/j.1365-2613.2011.00764.x] [Cited by in Crossref: 219] [Cited by in F6Publishing: 194] [Article Influence: 21.9] [Reference Citation Analysis]
169 Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis--implications for nephrologists. Eur J Radiol 2008;66:208-12. [PMID: 18342470 DOI: 10.1016/j.ejrad.2008.01.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
170 Unruh C, Van Bavel N, Anikovskiy M, Prenner EJ. Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks. Molecules 2020;25:E5762. [PMID: 33297578 DOI: 10.3390/molecules25235762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
171 Hope TA, Leboit PE, High WA, Fu Y, Brasch RC. Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. Magnetic Resonance Imaging 2013;31:139-44. [DOI: 10.1016/j.mri.2012.06.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
172 Katahira N, Tanigawa T, Tanaka H, Nonoyama H, Ueda H. Diluted gadoteridol (ProHance®) causes mild ototoxicity in cochlear outer hair cells. Acta Otolaryngol 2013;133:788-95. [PMID: 23638948 DOI: 10.3109/00016489.2013.776177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
173 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
174 Plamondon I, Samson C, Watters AK, Bégin LR, Côté J, Déziel C, Quérin S. La fibrose systémique néphrogénique: nouveau coup dur pour les insuffisants rénaux. Néphrologie & Thérapeutique 2007;3:152-6. [DOI: 10.1016/j.nephro.2007.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
175 Thomsen HS; European Society of Urogenital Radiology (ESUR). ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007;17:2692-6. [PMID: 17977076 DOI: 10.1007/s00330-007-0744-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 80] [Article Influence: 9.0] [Reference Citation Analysis]
176 Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Radiology 2015;276:741-7. [DOI: 10.1148/radiol.2015142423] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
177 Hristov AC, High WA, Golitz LE. Localized cutaneous argyria. J Am Acad Dermatol 2011;65:660-1. [PMID: 21839327 DOI: 10.1016/j.jaad.2010.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
178 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
179 Kindberg GM, Uran S, Friisk G, Martinsen I, Skotland T. The fate of Gd and chelate following intravenous injection of gadodiamide in rats. Eur Radiol 2010;20:1636-43. [PMID: 20157815 DOI: 10.1007/s00330-010-1716-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
180 Nong Q, Chen X, Hu L, Huang Y, Luan T, Liu H, Chen B. Identification and characterization of Gd-binding proteins in NIH-3T3 cells. Talanta 2020;219:121281. [DOI: 10.1016/j.talanta.2020.121281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Lim YL, Lee HY, Low SCS, Chan LP, Goh NSG, Pang SM. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007;32:353-8. [DOI: 10.1111/j.1365-2230.2007.02412.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
182 Mohrs OK, Petersen SE, Schulze T, Zieschang M, Küx H, Schmitt P, Bergemann S, Kauczor H. High-Resolution 3D Unenhanced ECG-Gated Respiratory-Navigated MR Angiography of the Renal Arteries: Comparison With Contrast-Enhanced MR Angiography. American Journal of Roentgenology 2010;195:1423-8. [DOI: 10.2214/ajr.10.4365] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
183 Kalb B, Martin DR, Salman K, Sharma P, Votaw J, Larsen C. Kidney transplantation: structural and functional evaluation using MR Nephro-Urography. J Magn Reson Imaging. 2008;28:805-822. [PMID: 18821623 DOI: 10.1002/jmri.21562] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
184 Yantasee W, Fryxell GE, Porter GA, Pattamakomsan K, Sukwarotwat V, Chouyyok W, Koonsiripaiboon V, Xu J, Raymond KN. Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis. Nanomedicine 2010;6:1-8. [PMID: 19447204 DOI: 10.1016/j.nano.2009.05.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
185 Provenzale JM. Nephrogenic Systemic Fibrosis: Some Considerations on the Debate Regarding Its Cause. American Journal of Roentgenology 2008;191:1867-9. [DOI: 10.2214/ajr.08.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Chao C, Yang C, Hsiao C, Pan M, Lin C, Hsieh S. Nephrogenic Systemic Fibrosis Associated with Gadolinium Use. Journal of the Formosan Medical Association 2008;107:270-4. [DOI: 10.1016/s0929-6646(08)60147-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
187 Osterode W, Falkenberg G, Regele H. Gadolinium distribution in kidney tissue determined and quantified by micro synchrotron X-ray fluorescence. Biometals 2021;34:341-50. [PMID: 33486677 DOI: 10.1007/s10534-020-00284-8] [Reference Citation Analysis]
188 Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience. Journal of the American Academy of Dermatology 2010;63:389-99. [DOI: 10.1016/j.jaad.2009.10.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
189 Yantasee W, Sangvanich T, Creim JA, Pattamakomsan K, Wiacek RJ, Fryxell GE, Addleman RS, Timchalk C. Functional sorbents for selective capture of plutonium, americium, uranium, and thorium in blood. Health Phys 2010;99:413-9. [PMID: 20699706 DOI: 10.1097/HP.0b013e3181ce5f3e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
190 Foss C, Smith JK, Ortiz L, Hanevold C, Davis L. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy. Pediatr Dermatol 2009;26:579-82. [PMID: 19840315 DOI: 10.1111/j.1525-1470.2008.00802.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
191 Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford) 2014;53:1613-7. [PMID: 24706993 DOI: 10.1093/rheumatology/keu151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
192 Kadiyala D, Roer DA, Perazella MA. Nephrogenic Systemic Fibrosis Associated With Gadoversetamide Exposure: Treatment With Sodium Thiosulfate. American Journal of Kidney Diseases 2009;53:133-7. [DOI: 10.1053/j.ajkd.2008.09.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
193 Shin K, Granter SR, Coblyn JS, Gupta S. Progressive arm and leg stiffness in a patient with chronic renal impairment. Nat Rev Rheumatol 2008;4:557-62. [DOI: 10.1038/ncprheum0883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
194 Amet S, Launay-Vacher V, Clément O, Frances C, Tricotel A, Stengel B, Gauvrit JY, Grenier N, Reinhardt G, Janus N, Choukroun G, Laville M, Deray G. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol 2014;49:109-15. [PMID: 24169070 DOI: 10.1097/RLI.0000000000000000] [Cited by in Crossref: 53] [Cited by in F6Publishing: 10] [Article Influence: 7.6] [Reference Citation Analysis]
195 Hope TA, Doherty A, Fu Y, Aslam R, Qayyum A, Brasch RC. Gadolinium accumulation and fibrosis in the liver after administration of gadoxetate disodium in a rat model of active hepatic fibrosis. Radiology 2012;264:423-7. [PMID: 22570507 DOI: 10.1148/radiol.12112453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
196 Lin S, Brown JJ. MR contrast agents: Physical and pharmacologic basics. J Magn Reson Imaging 2007;25:884-99. [DOI: 10.1002/jmri.20955] [Cited by in Crossref: 180] [Cited by in F6Publishing: 121] [Article Influence: 12.9] [Reference Citation Analysis]
197 Weng TI, Chen HJ, Lu CW, Ho YC, Wu JL, Liu SH, Hsiao JK. Exposure of Macrophages to Low-Dose Gadolinium-Based Contrast Medium: Impact on Oxidative Stress and Cytokines Production. Contrast Media Mol Imaging 2018;2018:3535769. [PMID: 30627059 DOI: 10.1155/2018/3535769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
198 Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007;2:199-205. [PMID: 17712863 DOI: 10.1002/cmmi.146] [Cited by in Crossref: 142] [Cited by in F6Publishing: 117] [Article Influence: 10.1] [Reference Citation Analysis]
199 Zhang M, Zhai X, Sun M, Ma T, Huang Y, Huang B, Du Y, Yan C. When rare earth meets carbon nanodots: mechanisms, applications and outlook. Chem Soc Rev 2020;49:9220-48. [PMID: 33165456 DOI: 10.1039/d0cs00462f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
200 Zhang B, Liang L, Chen W, Liang C, Zhang S. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. PLoS One 2015;10:e0129720. [PMID: 26076348 DOI: 10.1371/journal.pone.0129720] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
201 Prchal D, Holmes D, Levin A. Nephrogenic systemic fibrosis: the story unfolds. Kidney International 2008;73:1335-7. [DOI: 10.1038/ki.2008.157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
202 Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology 2011;64:91-6. [DOI: 10.1016/j.jaad.2009.12.044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
203 Sigovan M, Gasper W, Alley HF, Owens CD, Saloner D. USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 2012;265:584-90. [PMID: 22875796 DOI: 10.1148/radiol.12112694] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
204 Tweedle MF. Gadolinium deposition: Is it chelated or dissociated gadolinium? How can we tell? Magnetic Resonance Imaging 2016;34:1377-82. [DOI: 10.1016/j.mri.2016.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
205 Kaewlai R, Abujudeh H. Nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2012;199:W17-W23. [PMID: 22733927 DOI: 10.2214/ajr.11.8144] [Cited by in Crossref: 78] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
206 Springer F, Günther RW, Schmitz-Rode T. Aneurysm Sac pressure measurement with minimally invasive implantable pressure sensors: an alternative to current surveillance regimes after EVAR? Cardiovasc Intervent Radiol 2008;31:460-7. [PMID: 18087767 DOI: 10.1007/s00270-007-9245-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
207 Penfield JG, Reilly RF. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium-Based Contrast Agents?: GADOLINIUM CHELATE DIFFERENCES AND NSF RISK. Seminars in Dialysis 2008;21:129-34. [DOI: 10.1111/j.1525-139x.2007.00408.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
208 Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23. [PMID: 20570839 DOI: 10.1136/ard.2009.127761] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
209 Liu HS, Jawad AF, Laney N, Hartung EA, Furth SL, Detre JA. Effect of blood T1 estimation strategy on arterial spin labeled cerebral blood flow quantification in children and young adults with kidney disease. J Neuroradiol 2019;46:29-35. [PMID: 29604324 DOI: 10.1016/j.neurad.2018.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
210 Do C, Barnes JL, Tan C, Wagner B. Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 2014;307:F844-55. [PMID: 25100280 DOI: 10.1152/ajprenal.00379.2014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
211 Wiedemeyer K, Kutzner H, Abraham JL, Thakral C, Carlson JA, Tran TA, Hausser I, Hartschuh W. The Evolution of Osseous Metaplasia in Localized Cutaneous Nephrogenic Systemic Fibrosis: A Case Report. The American Journal of Dermatopathology 2009;31:674-81. [DOI: 10.1097/dad.0b013e3181a1fb55] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
212 Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-parker S, Martin DR. Nephrogenic systemic fibrosis: Center case review. J Magn Reson Imaging 2007;26:1198-203. [DOI: 10.1002/jmri.21136] [Cited by in Crossref: 94] [Cited by in F6Publishing: 76] [Article Influence: 6.7] [Reference Citation Analysis]
213 Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-75. [PMID: 18501784 DOI: 10.1053/j.ajkd.2007.12.036] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
214 Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, Swartz RD. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009;44:74-81. [PMID: 19077912 DOI: 10.1097/RLI.0b013e31818f76b5] [Cited by in Crossref: 66] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
215 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
216 Caccetta T, Chan JJ. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium: Nephrogenic systemic fibrosis. Australasian Journal of Dermatology 2008;49:48-51. [DOI: 10.1111/j.1440-0960.2007.00426.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
217 Bryant B, Im K, Broome D. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clinical Radiology 2009;64:706-13. [DOI: 10.1016/j.crad.2009.04.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
218 Fu C, Zhang C, Peng H, Han F, Baker C, Wu Y, Ta H, Whittaker AK. Enhanced Performance of Polymeric 19 F MRI Contrast Agents through Incorporation of Highly Water-Soluble Monomer MSEA. Macromolecules 2018;51:5875-82. [DOI: 10.1021/acs.macromol.8b01190] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
219 Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 2011;46:292-300. [PMID: 21263333 DOI: 10.1097/RLI.0b013e3182056ccf] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
220 Wieszczycka K, Staszak K, Woźniak-budych MJ, Jurga S. Lanthanides and tissue engineering strategies for bone regeneration. Coordination Chemistry Reviews 2019;388:248-67. [DOI: 10.1016/j.ccr.2019.03.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
221 Fu C, Herbst S, Zhang C, Whittaker AK. Polymeric 19 F MRI agents responsive to reactive oxygen species. Polym Chem 2017;8:4585-95. [DOI: 10.1039/c7py00986k] [Cited by in Crossref: 40] [Article Influence: 10.0] [Reference Citation Analysis]
222 Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009;30:1335-40. [DOI: 10.1002/jmri.21976] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
223 Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30:1259-1267. [PMID: 19938038 DOI: 10.1002/jmri.21969] [Cited by in Crossref: 343] [Cited by in F6Publishing: 276] [Article Influence: 31.2] [Reference Citation Analysis]
224 Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. Radiology 2009;250:371-7. [PMID: 19188312 DOI: 10.1148/radiol.2502080498] [Cited by in Crossref: 177] [Cited by in F6Publishing: 130] [Article Influence: 14.8] [Reference Citation Analysis]
225 Nortier JL, del Marmol V. Nephrogenic systemic fibrosis the need for a multidisciplinary approach. Nephrology Dialysis Transplantation 2007;22:3097-101. [DOI: 10.1093/ndt/gfm430] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
226 Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2024-33. [PMID: 20959327 DOI: 10.1136/ard.2010.134858] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
227 Abraham JL, Chandra S, Thakral C, Abraham JM. SIMS imaging of gadolinium isotopes in tissue from Nephrogenic Systemic Fibrosis patients: Release of free Gd from magnetic resonance imaging (MRI) contrast agents. Applied Surface Science 2008;255:1181-4. [DOI: 10.1016/j.apsusc.2008.05.140] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
228 Sanyal S, Marckmann P, Scherer S, Abraham JL. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review. Nephrology Dialysis Transplantation 2011;26:3616-26. [DOI: 10.1093/ndt/gfr085] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
229 Dawson P, Punwani S. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Non-Gadolinium Options for the Imaging of CKD/ESRD Patients: NSF AND IMAGING STRATEGIES. Seminars in Dialysis 2008;21:160-5. [DOI: 10.1111/j.1525-139x.2007.00401.x] [Cited by in Crossref: 17] [Article Influence: 1.3] [Reference Citation Analysis]
230 Blondin D, Koester A, Andersen K, Kurz KD, Moedder U, Cohnen M. Renal transplant failure due to urologic complications: Comparison of static fluid with contrast-enhanced magnetic resonance urography. Eur J Radiol 2009;69:324-30. [PMID: 18055152 DOI: 10.1016/j.ejrad.2007.10.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
231 Saab G, Abu-alfa A. Will Dialysis Prevent the Development of Nephrogenic Systemic Fibrosis After Gadolinium-Based Contrast Administration? American Journal of Roentgenology 2007;189:W169-W169. [DOI: 10.2214/ajr.07.2252] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
232 Boyd AS, Sanyal S, Abraham JL. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. Journal of the American Academy of Dermatology 2008;59:356-8. [DOI: 10.1016/j.jaad.2008.01.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
233 Beckett KR, Moriarity AK, Langer JM. Safe Use of Contrast Media: What the Radiologist Needs to Know. RadioGraphics 2015;35:1738-50. [DOI: 10.1148/rg.2015150033] [Cited by in Crossref: 120] [Cited by in F6Publishing: 66] [Article Influence: 20.0] [Reference Citation Analysis]
234 Wang J, Salzillo T, Jiang Y, Mackeyev Y, David Fuller C, Chung C, Choi S, Hughes N, Ding Y, Yang J, Vedam S, Krishnan S. Stability of MRI contrast agents in high-energy radiation of a 1.5T MR-Linac. Radiother Oncol 2021;161:55-64. [PMID: 34089753 DOI: 10.1016/j.radonc.2021.05.023] [Reference Citation Analysis]
235 Clases D, Sperling M, Karst U. Analysis of metal-based contrast agents in medicine and the environment. TrAC Trends in Analytical Chemistry 2018;104:135-47. [DOI: 10.1016/j.trac.2017.12.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
236 Michaely H, Thomsen H, Reiser M, Schoenberg S. Nephrogene systemische Fibrose (NSF) – Implikationen für die Radiologie. Radiologe 2007;47:785-93. [DOI: 10.1007/s00117-007-1537-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
237 Leiner T, Herborn CU, Goyen M. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 2007;17:1921-3. [PMID: 17458550 DOI: 10.1007/s00330-007-0663-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
238 Huckle JE, Altun E, Jay M, Semelka RC. Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited In Vivo? Invest Radiol. 2016;51:236-240. [PMID: 26588463 DOI: 10.1097/rli.0000000000000228] [Cited by in Crossref: 38] [Cited by in F6Publishing: 8] [Article Influence: 7.6] [Reference Citation Analysis]
239 Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA. Nephrogenic systemic fibrosis: A clinicopathologic study of six cases. Journal of the American Academy of Dermatology 2007;57:105-11. [DOI: 10.1016/j.jaad.2007.02.021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
240 Cowell GW, Reid AW, Roditi GH. Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging. Insights Imaging 2012;3:495-504. [PMID: 22865510 DOI: 10.1007/s13244-012-0188-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
241 Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009;30:1249-58. [PMID: 19938037 DOI: 10.1002/jmri.21967] [Cited by in Crossref: 117] [Cited by in F6Publishing: 89] [Article Influence: 10.6] [Reference Citation Analysis]
242 Kelly BC, Markle LS, Vickers JL, Petitt MS, Raimer SS, McNeese C. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. J Am Acad Dermatol 2010;63:483-9. [PMID: 20708474 DOI: 10.1016/j.jaad.2009.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
243 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 11.1] [Reference Citation Analysis]
244 Lima XT, Alora-palli MB, Kimball AB, Kay J. Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. Arthritis Care Res 2013;65:637-42. [DOI: 10.1002/acr.21877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
245 Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol. 2008;158:607-610. [PMID: 18076707 DOI: 10.1111/j.1365-2133.2007.08369.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
246 Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010;31:440-6. [PMID: 20099361 DOI: 10.1002/jmri.22024] [Cited by in Crossref: 84] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
247 . Quiz Page February 2008. American Journal of Kidney Diseases 2008;51:A33-4. [DOI: 10.1053/j.ajkd.2007.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
248 Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic Systemic Fibrosis. Journal of the American College of Cardiology 2009;53:1621-8. [DOI: 10.1016/j.jacc.2008.12.061] [Cited by in Crossref: 123] [Cited by in F6Publishing: 85] [Article Influence: 10.3] [Reference Citation Analysis]
249 Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008;38:489-496; quiz 602-603. [PMID: 17943276 DOI: 10.1007/s00247-007-0633-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
250 Sharma J, Mongia A, Schoenaman M, Chang S, D'Angelo A, Rao M. Nephrogenic fibrosing dermatopathy, cardiac calcification and pulmonary hypertension in an adolescent on chronic hemodialysis. Indian J Nephrol 2008;18:70-3. [PMID: 20142906 DOI: 10.4103/0971-4065.42340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
251 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
252 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]
253 Du F, Zhang L, Zhang L, Zhang M, Gong A, Tan Y, Miao J, Gong Y, Sun M, Ju H, Wu C, Zou S. Engineered gadolinium-doped carbon dots for magnetic resonance imaging-guided radiotherapy of tumors. Biomaterials 2017;121:109-20. [PMID: 28086179 DOI: 10.1016/j.biomaterials.2016.07.008] [Cited by in Crossref: 88] [Cited by in F6Publishing: 62] [Article Influence: 17.6] [Reference Citation Analysis]
254 Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543-2548. [PMID: 18668587 DOI: 10.1002/art.23696] [Cited by in Crossref: 116] [Cited by in F6Publishing: 89] [Article Influence: 8.9] [Reference Citation Analysis]
255 Schäd SG, Heitland P, Kühn-velten WN, Gross GE, Jonas L. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure: Gadolinium in nephrogenic fibrosis. J Cutan Pathol 2013;40:935-44. [DOI: 10.1111/cup.12214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
256 Igreja ACDSM, Mesquita KDC, Cowper SE, Costa IMC. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol 2012;87:597-607. [DOI: 10.1590/s0365-05962012000400013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
257 Saxena SK, Sharma M, Patel M, Oreopoulos D. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol 2008;40:715-24. [PMID: 18418727 DOI: 10.1007/s11255-008-9361-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
258 Dawson P. Nephrogenic systemic fibrosis: Possible mechanisms and imaging management strategies. J Magn Reson Imaging 2008;28:797-804. [DOI: 10.1002/jmri.21521] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
259 Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258-263. [PMID: 17699422 DOI: 10.2215/cjn.03250906] [Cited by in Crossref: 108] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
260 Forton SM, Latourette MT, Parys M, Kiupel M, Shahriari D, Sakamoto JS, Shapiro EM. In Vivo Microcomputed Tomography of Nanocrystal-Doped Tissue Engineered Scaffolds. ACS Biomater Sci Eng 2016;2:508-16. [PMID: 30035211 DOI: 10.1021/acsbiomaterials.5b00476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
261 Heymann WR. Nephrogenic systemic fibrosis—The beginning of the end? Journal of the American Academy of Dermatology 2007;57:171-2. [DOI: 10.1016/j.jaad.2007.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
262 Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012;19:806-11. [PMID: 22571387 DOI: 10.1111/j.1442-2042.2012.03042.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
263 Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009;61:537-52. [PMID: 19131226 DOI: 10.1016/j.etp.2008.11.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
264 Eichhorn J, Ley S. Angeborene Fehlbildungen der Aorta im Kindes- und Jugendalter. Radiologe 2007;47:974-81. [DOI: 10.1007/s00117-007-1575-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
265 Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-199. [PMID: 18325705 DOI: 10.1016/j.ejrad.2008.01.016] [Cited by in Crossref: 89] [Cited by in F6Publishing: 70] [Article Influence: 6.8] [Reference Citation Analysis]
266 Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008;59:218-24. [PMID: 18538448 DOI: 10.1016/j.jaad.2008.04.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
267 Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008;180:830-5; discussion 835. [PMID: 18635232 DOI: 10.1016/j.juro.2008.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
268 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
269 Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic Systemic Fibrosis: A Chemical Perspective. Radiology 2008;247:608-12. [DOI: 10.1148/radiol.2473071975] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
270 Haylor J, Schroeder J, Wagner B, Nutter F, Jestin G, Idée J, Morcos S. Skin Gadolinium Following Use of MR Contrast Agents in a Rat Model of Nephrogenic Systemic Fibrosis. Radiology 2012;263:107-16. [DOI: 10.1148/radiol.12110881] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
271 Perazella MA. Nephrogenic Systemic Fibrosis, Kidney Disease, and Gadolinium: Is There a Link?: Figure 1. CJASN 2007;2:200-2. [DOI: 10.2215/cjn.00030107] [Cited by in Crossref: 80] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
272 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
273 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
274 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
275 Rosenkranz AR, Grobner T, Mayer GJ. Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? Wien Klin Wochenschr 2007;119:271-5. [DOI: 10.1007/s00508-007-0801-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
276 High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP. Gadolinium deposition in nephrogenic systemic fibrosis: An examination of tissue using synchrotron x-ray fluorescence spectroscopy. Journal of the American Academy of Dermatology 2010;62:38-44. [DOI: 10.1016/j.jaad.2009.07.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
277 Walker JP, Nosova E, Sigovan M, Rapp J, Grenon MS, Owens CD, Gasper WJ, Saloner DA. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. Ann Vasc Surg 2015;29:63-8. [PMID: 25269682 DOI: 10.1016/j.avsg.2014.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
278 Ley-Zaporozhan J, Kreitner KF, Unterhinninghofen R, Helm E, Puderbach M, Schenk JP, Deshpande V, Krummenauer F, Szabo G, Kauczor HU, Ley S. Assessment of thoracic aortic dimensions in an experimental setting: comparison of different unenhanced magnetic resonance angiography techniques with electrocardiogram-gated computed tomography angiography for possible application in the pediatric population. Invest Radiol 2008;43:179-86. [PMID: 18301314 DOI: 10.1097/RLI.0b013e31815f8870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
279 Liszewski MC, Ciet P, Sodhi KS, Lee EY. Updates on MRI Evaluation of Pediatric Large Airways. American Journal of Roentgenology 2017;208:971-81. [DOI: 10.2214/ajr.16.17132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
280 Leung N, Pittelkow MR, Lee CU, Good JA, Hanley MM, Moyer TP. Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. NDT Plus 2009;2:309-11. [PMID: 25984024 DOI: 10.1093/ndtplus/sfp042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
281 Manger B. Nephrogene systemische Fibrose: Medizinische Detektivarbeit im 21. Jahrhundert. Z Rheumatol 2007;66:533-5. [DOI: 10.1007/s00393-007-0186-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
282 Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5:157-170. [PMID: 19190625 DOI: 10.1038/ncpneph1040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]